Buried in Trump’s executive order on drug pricing is a windfall clause for pharma
by Emily Kopp, Kaiser Health News
Jul 12, 2017
3 minutes
The pharmaceutical industry could see windfall profits from a little-noticed tweak to the insurance market tucked into the Trump administration’s draft executive order on drug prices, experts say.
The short, technical paragraph calls for the Internal Revenue Service to allow patients with high-deductible health plans to receive care for chronic diseases, including drugs, before meeting their deductibles.
This allowance, known as a “safe harbor,” could be welcome news for patients with chronic conditions like diabetes or asthma stuck with skimpy plans. For example, a diabetes patient could fill her prescription for insulin with just
You’re reading a preview, subscribe to read more.
Start your free 30 days